Kansikuva

Cost-Effectiveness Analysis of Sacubitril/Valsartan Compared to Enalapril for Heart Failure Patients in Indonesia

Neily Zakiyah,1,2 Rano K Sinuraya,1- 3 Arif SW Kusuma,2,4 Auliya A Suwantika,1,2,5 Keri Lestari1,2 1Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Bandung, Indonesia; 2Center of Excellence in Higher Education for Pharmaceutical Care Innovation, Univer...

Tallennettuna:

Bibliografiset tiedot
Päätekijät:	Zakiyah N (Tekijä), Sinuraya RK (Tekijä), Kusuma ASW (Tekijä), Suwantika AA (Tekijä), Lestari K (Tekijä)
Aineistotyyppi:	Kirja
Julkaistu:	Dove Medical Press, 2021-10-01T00:00:00Z.
Aiheet:	article
Linkit:	Connect to this object online.
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia

Sacubitril/Valsartan versus enalapril in nonischemic heart failure in Paradigm-Hf trial
Tekijä: Mohammed Habib
Julkaistu: (2018)

Sacubitril-Valsartan Compared With Enalapril for the Treatment of Heart Failure: A Decision-Analytic Markov Model Simulation in China
Tekijä: Yue Wu, et al.
Julkaistu: (2020)

Sacubitril-valsartan versus enalapril for the treatment of acute decompensated heart failure in Chinese settings: A cost-effectiveness analysis
Tekijä: Tianyang Hu, et al.
Julkaistu: (2023)

The Efficacy and Safety of Sacubitril/Valsartan in Heart Failure Patients: A Review
Tekijä: Rui Zhang MD, PhD, et al.
Julkaistu: (2022)

Cardiovascular Outcomes with Sacubitril-Valsartan in Heart Failure: Emerging Clinical Data
Tekijä: Cuthbert JJ, et al.
Julkaistu: (2020)

Sacubitril with valsartan, a modern pharmacotherapy in heart failure - a literature review
Tekijä: Bartosz Sadłowski, et al.
Julkaistu: (2024)

Dapagliflozin versus sacubitril-valsartan for heart failure with mildly reduced or preserved ejection fraction
Tekijä: Ronen Arbel, et al.
Julkaistu: (2024)

Spotlight on valsartan–sacubitril fixed-dose combination for heart failure: the evidence to date
Tekijä: Vilela-Martin JF
Julkaistu: (2016)

Up-Titration of Sacubitril/Valsartan Among Patients With Heart Failure and Preserved Ejection Fraction
Tekijä: Koichiro Matsumura MD, et al.
Julkaistu: (2023)

Health‐related quality of life in patients with heart failure eligible for treatment with sacubitril-valsartan
Tekijä: Lena Holmlund, et al.
Julkaistu: (2020)

Longitudinal Trajectory Modeling to Assess Adherence to Sacubitril/Valsartan among Patients with Heart Failure
Tekijä: Sara Mucherino, et al.
Julkaistu: (2023)

Natriuretic peptide pathways in heart failure in the context of the analysis of the mechanism of action and potential usages of sacubitril/valsartan
Tekijä: Kamila Babkiewicz-Jahn, et al.
Julkaistu: (2024)

Short-term effect of sacubitril/valsartan on endothelial dysfunction and arterial stiffness in patients with chronic heart failure
Tekijä: Velia Cassano, et al.
Julkaistu: (2022)

Duration of Heart Failure With Reduced Ejection Fraction Associated With Electrocardiographic Outcomes Before and After Sacubitril/Valsartan
Tekijä: Po-Lin Lin MD, et al.
Julkaistu: (2022)

Supramolecular complex sacubitril/valsartan - the first representative of a new class of drugs for the treatment of chronic heart failure
Tekijä: T. V. Ashcheulova, et al.
Julkaistu: (2019)

Benefits and adverse effects of sacubitril/valsartan in patients with chronic heart failure: A systematic review and meta‐analysis
Tekijä: Elodie Charuel, et al.
Julkaistu: (2021)

An Evaluation of the Initiation and Use of Sacubitril/Valsartan in an Inpatient Heart Failure Population: A Retrospective Medication Use Evaluation
Tekijä: Tara Snyder, et al.
Julkaistu: (2019)

Molecular mechanisms of sacubitril/valsartan in cardiac remodeling
Tekijä: Nor Hidayah Mustafa, et al.
Julkaistu: (2022)

Sacubitril/valsartan in real-life clinical practice
Tekijä: Yüksel Çavuşoğlu
Julkaistu: (2021)

Effects of sacubitril-valsartan on heart failure patients with mid-range ejection fractions: A systematic review and meta-analysis
Tekijä: Jianbin Qin, et al.
Julkaistu: (2022)

EFFECTS OF SACUBITRIL/VALSARTAN ON THE ARTERIAL STIFFNESS AND LEFT VENTRICULAR-ARTERIAL COUPLING IN PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION
Tekijä: Zh. D. Kobalava, et al.
Julkaistu: (2018)

Case Report: Low Dose of Valsartan/Sacubitril Leads to Successful Reversal of Acute Heart Failure in Chemotherapy-Induced Cardiomyopathy
Tekijä: Shih-Hsing Lo, et al.
Julkaistu: (2021)

Sacubitril/valsartan: evaluation of safety and efficacy as an antihypertensive treatment
Tekijä: Sarah L Anderson, et al.
Julkaistu: (2018)

Pathogenetic justification of sacubitril / valsartan use in respiratory-cardial comorbidity
Tekijä: T. V. Ashcheulova, et al.
Julkaistu: (2023)

The concentration of maternal sacubitril/valsartan transferred into human milk is negligible
Tekijä: Sirin Falconi, et al.
Julkaistu: (2024)

Corrigendum: The concentration of maternal sacubitril/valsartan transferred into human milk is negligible
Tekijä: Sirin Falconi, et al.
Julkaistu: (2024)

Exploring the Food and Drug Administration's review and approval of Entresto (sacubitril/valsartan)
Tekijä: Ashley L. Eadie, et al.
Julkaistu: (2021)

EFFECT OF SACUBITRIL/VALSARTAN ON NATRIURESIS, DIURESIS AND BLOOD PRESSURE IN HYPERTENSIVE PATIENTS
Tekijä: Zh. D. Kobalava, et al.
Julkaistu: (2017)

Sacubitril/valsartan: research progress of multi-channel therapy for cardiorenal syndrome
Tekijä: Shuangcui Wang, et al.
Julkaistu: (2023)

Cost-Effectiveness Analysis of Chemoradiation and Radiotherapy Treatment for Stage IIB and IIIB Cervical Cancer Patients
Tekijä: Puspitasari IM, et al.
Julkaistu: (2021)

The efficacy and safety of sacubitril/valsartan compared with ACEI/ARB in the treatment of heart failure following acute myocardial infarction: a systematic review and meta-analysis of randomized controlled trials
Tekijä: Jinquan Gao, et al.
Julkaistu: (2023)

Cost-effectiveness of cardiomyopathy ambulatory care with sacubitril/valsartan vs standard therapy after COVID-19 in Kazakhstan
Tekijä: Dana Dadanbekova, et al.
Julkaistu: (2024)

Changes in urinary output due to concomitant administration of sacubitril/valsartan and atrial natriuretic peptide in patients with heart failure: a multicenter retrospective cohort study
Tekijä: Tatsuki Yanagawa, et al.
Julkaistu: (2024)

Evaluating the safety and tolerability of inpatient sacubitril/valsartan initiation in a community hospital
Tekijä: Katie L. Peppin, et al.
Julkaistu: (2020)

Looking into the Kinetics of NT-proBNP and sST2 Changes in Patients with Heart Failure Treated with Sacubitril/Valsartan: A Hint to Different Therapeutic Pathways
Tekijä: Massimo Mapelli, et al.
Julkaistu: (2023)

Sacubitril-valsartan for the treatment of hypertension in China: A cost-utility analysis based on meta-analysis of randomized controlled trials
Tekijä: Yake Lou, et al.
Julkaistu: (2022)

Enalapril and Enalaprilat Pharmacokinetics in Children with Heart Failure Due to Dilated Cardiomyopathy and Congestive Heart Failure after Administration of an Orodispersible Enalapril Minitablet (LENA-Studies)
Tekijä: Stephanie Laeer, et al.
Julkaistu: (2022)

Cost-Effectiveness of Ferrous Fumarate–Folic Acid and Ferrous Gluconate–Multivitamins in a High Prevalence Area of Iron Deficiency Anemia in Indonesia
Tekijä: Rakanita Y, et al.
Julkaistu: (2021)

COMPARATIVE EFFICACY OF ACE INHIBITORS (RAMIPRIL VS ENALAPRIL) IN TREATMENT OF CHRONIC HEART FAILURE IN WOMEN
Tekijä: S. N. Tereshchenko, et al.
Julkaistu: (2016)

Detection of muscular system adverse reaction signals in sacubitril/valsartan treatment combined with statins
Tekijä: Fukun Zhao, et al.
Julkaistu: (2024)